NCT05484206View on ClinicalTrials.gov

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

PHASE1RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

September 21, 2022

Primary Completion Date

September 25, 2026

Study Completion Date

April 30, 2027

Conditions
Hepatic ImpairmentCirrhosis
Interventions
DRUG

VIR-2218

VIR-2218 given by subcutaneous injection.

DRUG

VIR-3434

VIR-3434 given by subcutaneous injection.

Trial Locations (5)

33016

RECRUITING

Floridian Clinical Research, Miami Lakes

33024

WITHDRAWN

CenExel Research Centers of America, Hollywood

78215

TERMINATED

Texas Liver Institute, San Antonio

92377

RECRUITING

Inland Empire Clinical Trials, Rialto

92790

RECRUITING

Orange County Research Center, Tustin

All Listed Sponsors
lead

Vir Biotechnology, Inc.

INDUSTRY